Humulin R 100 [iU]/mL (Insulin human INJECTION, SOLUTION) 100 [iU]/mL

Insulin human binds to insulin receptors on cells and triggers signaling pathways that increase glucose uptake and use. It also reduces the liver’s production of glucose. This pharmacologic action helps replace or supplement the body’s own insulin activity in people who require exogenous insulin.

The usual dose is not fixed in the product description because insulin dosing is individualized. A prescriber determines the regimen based on blood glucose readings, diabetes type, food intake, and other clinical factors. Patients should use only the dose and schedule provided by their healthcare professional.

Insulin products are commonly used when insulin therapy is needed during pregnancy, and treatment decisions should be made by a clinician. For breastfeeding, insulin is generally considered compatible with nursing because it is a peptide hormone, but monitoring and dose review may still be needed. The prescriber should guide treatment in both situations.

Submit the enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team then responds with pricing, availability, shipping details, including cold-chain handling where relevant, and the import paperwork.

Humulin R is insulin human, a short-acting insulin used as part of insulin therapy. Compared with longer-acting insulins, it is designed for prandial or general glucose control rather than sustained basal coverage. The best option depends on the patient’s treatment plan, glucose patterns, and prescriber preference.

As an injectable insulin product, it should be stored refrigerated at 2-8°C, protected from light, and not frozen or shaken. Handling should follow the product label and pharmacy instructions. Before use, users should confirm that the solution and packaging remain acceptable for administration.

Humulin R is given by parenteral administration as an injection solution. The exact route, technique, and schedule are determined by the prescriber and the product labeling. Patients should receive training from a healthcare professional on correct handling and administration.

The most important serious risk is severe hypoglycemia, which can cause confusion, loss of consciousness, seizure, or other urgent symptoms. Other serious risks include hypokalemia and rare severe allergic reactions. Patients should know the warning signs and seek urgent medical help if severe symptoms occur.

Humulin R should not be used in people with known hypersensitivity to insulin human or any ingredient in the formulation. It is also inappropriate when insulin therapy has not been prescribed for the individual condition. A clinician should review allergies, prior reactions, and the planned insulin regimen before use.